Outset Medical, Inc. (OM) Research And Development — Allocated Share Based Compensation Expense — Quarterly & Annual

Screener

Other product segments

General And Administrative

$1.61M-1.1%

Sales And Marketing

$416K-55.4%

Cost Of Revenue

$77K-58.6%

Similar metrics at other companies

OKURClinical Research — Allocated Share Based Compensation Expense

$2.78M+1.3%

FLGTTherapeutic Development — Allocated Share Based Compensation Expense

$2.25M+11.5%

NTNXProduct — Allocated Share Based Compensation Expense

$364K-9.2%

NTNXService — Allocated Share Based Compensation Expense

$5.71M-13.8%

SAFXContractor — Allocated Share Based Compensation Expense

$524.33K—

LNSRProduct — Allocated Share Based Compensation Expense

$55K+48.6%

Other financials

Income statement

Revenue$31.6M+0.7%

Gross profit$13.3M+11.9%

Operating income-$15.7M+7.1%

Net income-$18.0M+3.0%

EPS (diluted)-$0.97+6.7%

Balance sheet

Cash & equivalents$35.0M-11.5%

Total debt$104.4M+6.1%

Total equity$96.3M-37.8%

Total assets$242.4M-16.1%

Cash flow

Operating cash flow-$9.6M-99.8%

CapEx$111.0K-62.0%

Free cash flow-$9.7M-90.5%

Valuation

Market cap$90.83M-58.9%

Enterprise value$160.28M-42.7%

P/S0.8×-1.1×

Profitability

Gross margin41.8%+5.3pp

Operating margin-56.1%-7.4pp

Net margin-63.1%-11.9pp

FCF margin-33%-9.8pp

Returns & leverage

Return on equity-59.2%-14.5pp

Debt / equity1.1×+0.4×

Current ratio5.2×-2.3×

Where this comes from

Reported directly by Outset Medical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.

The source filing: Outset Medical, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 5:15 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001193125-26-338432

Line item	Three Months Ended / June 30, 2026	Three Months Ended / June 30, 2025	Six Months Ended / June 30, 2026	Six Months Ended / June 30, 2025
Cost of revenue	$77	$186	$188	$303
Research and development	594	750	1,414	1,309
Sales and marketing	416	933	874	1,412
General and administrative	1,609	1,627	3,673	3,449
Total stock-based compensation expense	$2,696	$3,496	$6,149	$6,473

Item 1. Financial Statements (Unaudited).

FAQ

What is Outset Medical, Inc.'s research and development — allocated share based compensation expense?: Outset Medical, Inc. (OM) reported research and development — allocated share based compensation expense of $594K in Q2 2026.
What does research and development — allocated share based compensation expense mean?: This metric represents the portion of total share-based compensation expense specifically attributed to the research and development function. It reflects the non-cash cost of equity-based incentives provided to personnel involved in the innovation, engineering, and clinical development of medical technology products. Tracking this allocation helps investors understand the true underlying investment in product pipeline development and human capital retention within the R&D organization.

Ask your AI about Outset Medical, Inc.'s research and development — allocated share based compensation expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Harbor at dusk